Clinical studies of chemotherapy efficacy in combination with androgenic deprivation in patients with oligometastatic hormone-sensitive prostate cancer
https://doi.org/10.21518/2079-701X-2019-19-170-175
Abstract
Prostate cancer is one of the most common malignant neoplasms in men. Nowadays, the overall mortality rate of this disease continues to increase, including due to the high frequency of primary detection of its widespread and metastatic forms. The effectiveness of hormone therapy of metastatic prostate cancer is limited in time, after which the disease progresses. The use of more aggressive strategies, including chemotherapy, in addition to androgenic deprivation in this category of patients may have some advantages and continues to be discussed. The article presents an overview of the results of clinical studies of docetaxel efficacy in combination with androgen-deprivational therapy in patients with oligometastatic hormone-sensitive prostate cancer. It has been determined that chemotherapy in patients with metastatic hormone-sensitive prostate cancer leads to an increase in the overall survival rate. The effectiveness of chemotherapy may depend on the amount of metastatic lesion. Although the higher efficacy of such treatment is noted in the case of a large volume of metastatic lesion, currently it is impossible to speak unequivocally about the need of adding docetaxel to the androgendeprivational therapy in patients with oligometastatic hormone-sensitive prostate cancer due to the limited statistical power of the presented data and heterogeneity of patients due to the lack of clearly defined criteria of oligometastases.
Taking into account these circumstances, future clinical studies to assess the effectiveness of chemotherapy in patients with oligometastatic hormone-sensitive prostate cancer and the analysis of their results can help to expand the boundaries of treatment strategies.
Taking into account these circumstances, future clinical studies to assess the effectiveness of chemotherapy in patients with oligometastatic hormone-sensitive prostate cancer and the analysis of their results can help to expand the boundaries of treatment strategies.
About the Author
S. V. Popov
Federal State Autonomous Educational Institution of Higher Education «Peoples’ Friendship University of Russia»
Russian Federation
Russian Federation
Dr. of Sci. (Med), Professor of the Department of General Medical Practice at the Medical Institute
6, Miklukho-Maklay St., 117198, Moscow, Russia
References
1. Kaprin A.D., Starinskiy V.V., Petrova G.V. (eds). State of Cancer Care in Russia in 2018. Moscow: Gertsen P.A. Moscow Cancer Research Institute – filial of TSYB Medical Radiological Research Center of the Ministry of Health of Russia; 2019. 236 с. (In Russ.) Available at: http://www.oncology.ru/service/statistics/condition/2018.pdf.
2. Alekseev B.Y., Andrianov A.N., Kaprin A.D. Current approaches to selection of the 1st line therapy in patients with metastatic hormone-sensitive prostate cancer. Onkourologiâ = Cancer Urology. 2017;13(4):85-90. (In Russ.) doi: 10.17650/1726-9776-2017-13-4-85-90.
3. Hellman S., Weichselbaum R.R. Oligometastases WRR. Oligometastases. J Clin Oncol. 1995;13:8–10. doi: 10.1200/JCO.1995.13.1.8.
4. Ost P., Jereczek- Fossa B.A., As N.V., Zilli T., Muacevic A., Olivier K. et al. Progression-free survival following stereotactic body radiotherapy for oligometastatic prostate cancer treatment-naive recurrence: a multi-institutional analysis. Eur Urol. 2016;69:9–12. doi: 10.1016/j.eururo.2015.07.004.
5. Pasqualetti F., Panichi M., Sainato A., Baldaccini D., Cocuzza P., Gonnelli A. et al. Image-guided stereotactic body radiotherapy in metastatic prostate cancer. Anticancer Res. 2018;38:3119–3122. doi: 10.21873/anticanres.12572.
6. Gravis G., Fizazi K., Joly F., Oudard S., Priou F., Esterni B. et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, openlabel, phase 3 trial. Lancet Oncol. 2013;14(2):149–158. doi: 10.1016/S1470-2045(12)70560-0.
7. Sweeney C.J., Chen Y.H., Carducci M., Liu G., Jarrard D.F., Eisenberger M. et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373:737–746. doi: 10.1056/NEJMoa1503747.
8. James N.D., Sydes M.R., Clarke N.W., Mason M.D., Dearnaley D.P., Spears M.R. et al.; STAMPEDE investigators. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387:1163–1177. doi: 10.1016/S0140-6736(15)01037-5.
9. Fizazi K., Jenkins C., Tannock I.F. Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra. Ann Oncol. 2015;26(8):1660–1667. doi: 10.1093/annonc/mdv245.
10. Shenoy N., Kohli M. Role of systemic chemotherapy in metastatic hormone-sensitive prostate cancer. Indian J Urol. 2016;32:257-261. doi: 10.4103/0970-1591.191234.
11. Puente J., Grande E., Medina A., Maroto P., Lainez N., Arranz J.A. Docetaxel in prostate cancer: a familiar face as the new standard in a hormone-sensitive setting. Ther Adv Med Oncol. 2017;9(5):307–318. doi: 10.1177/1758834017692779.
12. Vale C.L., Burdett S., Rydzewska L.H.M., Albiges L., Clarke N.W., Fisher D., et al., for the STOpCaP Steering Group. Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data. Lancet Oncol. 2016;17(2):243–256. doi: 10.1016/S1470-2045(15)00489-1.
13. Kapoor A. What’s New in Prostate Cancer Research? Highlights of GU-ASCO 2015. Can Urol Assoc J. 2015;9(5-6Suppl3):S148–S153. doi: 10.5489/cuaj.2994.
14. Botrel T.E.A., Clark O., Pompeo A.C.L., Bretas F.F.H., Sadi M.V., Ferreira U., Borges dos Reis R. Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis. PLoS One. 2016;11(6):e0157660. doi: 10.1371/journal.pone.0157660.
15. Damodaran S., Kyriakopoulos C.E., Jarrard D.F. Newly diagnosed metastatic prostate cancer – has the paradigm changed? Urol Clin North Am. 2017;44(4):611–621. doi: 10.1016/j.ucl.2017.07.008.
16. Kapoor A., Hotte S.J. Androgen receptor axis-targeted agents. Can Urol Assoc J. 2016;10(7-8Suppl3):S146–S148. doi: 10.5489/cuaj.4057.
17. Merseburger A.S., Alcaraz A., von Klot C.A. Androgen deprivation therapy as backbone therapy in the management of prostate cancer. Onco Targets Ther. 2016;9:7263–7274. doi: 10.2147/OTT.S117176.
18. Shiota M., Yokomizo A., Eto M. Taxane Chemotherapy for Hormone-Naïve Prostate Cancer with Its Expanding Role as Breakthrough Strategy. Front Oncol. 2015;5:304. doi: 10.3389/fonc.2015.00304.
19. Chen J., Zhang X., Sun G., Zhao J., Liu J., Zhao P., Dai J., Shen P., Zeng H. The effect of additional chemotherapy on high-risk prostate cancer: a systematic review and meta-analysis. Onco Targets Ther. 2018;11:9061–9070. doi: 10.2147/OTT.S187239.
20. Komura K., Sweeney C.J., Inamoto T., Ibuki N., Azuma H., Kantoff P.W. Current treatment strategies for advanced prostate cancer. Int J Urol. 2018;25(3):220–231. doi: 10.1111/iju.13512.
21. Sathianathen N.J., Philippou Y.A., Kuntz G.M., Konety B.R., Gupta S., Lamb A.D., Dahm P. Taxane‐based chemohormonal therapy for metastatic hormone‐sensitive prostate cancer. Cochrane Database Syst Rev. 2018;(10):CD012816. doi: 10.1002/14651858.CD012816.pub2.
22. Nader R., Amm J.E., Aragon-Ching J.B. Role of chemotherapy in prostate cancer. Asian J Androl. 2018;20(3):221-229. doi: 10.4103/aja.aja_40_17.
23. Gravis G. Systemic treatment for metastatic prostate cancer. Asian J Urol. 2019;6(2):162–168. doi: 10.1016/j.ajur.2019.02.002.
24. Hurwitz M.D. Chemotherapy and radiation for prostate cancer. Transl Androl Urol. 2018;7(3): 390–398. doi: 10.21037/tau.2018.03.07.
25. Miura Y., Horie S. The role of hormone therapy and chemotherapy in oligometastatic prostate cancer. ESMO Open. 2019;4(Suppl 1):e000471. doi: 10.1136/esmoopen-2018-000471.
26. Cornford P., Bellmunt J., Bolla M., Briers E., De Santis M., Gross T. et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol. 2017;71:630–642. doi: 10.1016/j.eururo.2016.08.002.
27. Gritskevich A.A., Mishugin S.V., Rusakov I.G. Possibilities of a combination of docetaxel with androgen deprivation in initial therapy of hormonesensitive prostate cancer. Medicinskij sovet = Medical Council. 2017;(6):94-97. (In Russ.) doi: 10.21518/2079-701X-2017-6-94-97.
28. Gravis G., Boher J.M., Joly F., Soulié M., Albiges L., Priou F. et al.; GETUG. Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non- castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 trial. Eur Urol. 2016;70:256–62. doi: 10.1016/j.eururo.2015.11.005.
29. Kyriakopoulos C.E., Chen Y.H., Carducci M.A., Liu G., Jarrard D.F., Hahn N.M. et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial. J Clin Oncol. 2018;36:1080–1087. doi: 10.1200/JCO.2017.75.3657.
30. Tucci M., Bertaglia V., Vignani F., Buttigliero C., Fiori C., Porpiglia F., Scagliotti G.V., Di Maio M. Addition of docetaxel to androgen deprivation therapy for patients with hormone-sensitive metastatic prostate cancer: a systematic review and meta-analysis. Eur Urol. 2016;69:563–573. doi: 10.1016/j.eururo.2015.09.013.
Review
For citations:
Popov SV. Clinical studies of chemotherapy efficacy in combination with androgenic deprivation in patients with oligometastatic hormone-sensitive prostate cancer. Meditsinskiy sovet = Medical Council. 2019;(19):170-175. (In Russ.) https://doi.org/10.21518/2079-701X-2019-19-170-175
Views:
658
Email this article 